Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, agosto 27
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Dare Bioscience Inc
DARE
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.7506
-0.0701
-8.54%
al cierre: Aug 25, 5:00 PM EST
$0.7688
-0.0519
-6.32%
Premercado: 7:46 AM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Dare Bioscience Financials
Dare Bioscience (DARE) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 55.56 percent increase over losses of $(0.45) per share from
Benzinga Newsdesk
PRO
Dare Bioscience Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $152.455K Miss $984.667K Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 60 percent increase over losses of $(0.50) per share from the
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
PRO
Dare Bioscience Q4 EPS $(0.02) Beats $(0.43) Estimate, Sales $1.024M Beat $375.750K Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.43) by 95.37 percent. This is a 96.92 percent increase over losses of $(0.65) per share from
Benzinga Newsdesk
Earnings Scheduled For March 26, 2026
Benzinga Insights
PRO
Dare Bioscience Q3 EPS $(0.28) Beats $(0.39) Estimate, Sales $2.262K Miss $9.750K Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.39) by 27.27 percent. This is a 49.09 percent increase over losses of $(0.55) per share from
Benzinga Newsdesk
Privacy Manager